WAKEFIELD, MA, Aug. 12 /CNW/ - NUCRYST Pharmaceuticals, a developer and
manufacturer of medical products that fight infection and inflammation, today
announced that its Board of Directors has authorized a program for the company
to repurchase up to 900,000 shares of its outstanding common stock for an
amount not to exceed $1.3 million using the facilities of NASDAQ.
